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Abstract 
Commensal bacteria in the colon may play a role in colorectal cancer (CRC) development. Recent studies from 
North America show Fusobacterium nucleatum (Fn) infection is over represented in disease tissue versus 
matched normal tissue in CRC patients. Using qPCR of DNA extracted from colorectal tissue biopsies and 
surgical resections of 3 European cohorts totalling 122 CRC patients we found overabundance of Fn in 
cancerous compared to matched normal tissue (p<0.0001). To determine whether Fn infection is an early event 
in CRC development, we assayed Fn in colorectal adenoma tissue (CRA,  #11) from 52 Irish patients. While for 
all CRAs Fn level was marginally significantly higher in disease versus normal tissue (p=0.06) it was 
significantly higher for high grade dysplasia (p=0.0148). As a secondary objective, we determined CRC patients 
with low Fn levels had a significantly longer overall survival time than patients with moderate and high levels 
of the bacterium (p=0.0083). Investigation of Fn as a potential non-invasive biomarker for CRC screening 
showed that while Fn was more abundant in stool samples from CRC patients compared to adenomas or 
controls, levels in stool did not correlate with cancer or adenoma tissue levels from the same individuals. This is 
the first study examining Fn in the colonic tissue and stool of  European CRC and CRA patients, and suggests 
Fn as a novel risk factor for disease progression from adenoma to cancer, possibly affecting patient survival 
outcomes. Our results highlight the potential of Fn detection as a diagnostic and prognostic determinant in CRC 
patients.  
 
 
Keywords: Colorectal cancer; neoplastic progression; bacterial infection.  
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Introduction 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide [1,2]. As most CRCs may 
develop slowly over years from precursor lesions, screening and early diagnosis are key to disease prevention 
[3].  
 
The human intestine is estimated to be colonized by more than 1000 bacterial phylotypes, which are thought to 
play important roles in nutrition and immune status, as well as many disease processes [4-6]. An altered 
presence of specific micro-organisms has been associated with a number of diseases of the gastro intestinal tract 
(GIT), such as inflammatory bowel disease (IBD) [7], irritable bowel syndrome (IBS,  #14) [8,9] and CRC [10-
12]. While its role remains unclear, Helicobacter pylori has long been associated with CRC [13] and 
intraepithelial Escherichia coli was also found to be present in the colonic mucosa of tumour and normal tissue 
from CRC patients [14]. In recent years several groups have appreciably expanded the evidence linking 
infectious agents to colonic disease development [15]. These micro-organisms are thought to create a 
microenvironment more favourable to CRC development [16]. It now seems that not only can the bacterial 
composition of the gut assist initiation and progression of colorectal tumours, but also that tumours can affect 
the representation of bacteria in their vicinity [10,12,17]. 
 
Microbiome sequencing studies have proven very successful in uncovering novel candidate bacterial species in 
tumour and stool samples from CRC patients [10,18,19]. In particular, two North American studies in 2012 
showed over-representation of Fusobacterium nucleatum (Fn) in CRC tumours versus surrounding normal 
tissue [20,21]. Fn is a highly invasive, gram-negative anaerobic bacterium and part of the oral and gut 
commensal flora [22] that has been linked to several diseases, such as periodontitis [23], appendicitis [24], 
Lemierre’s disease [25], and inflammatory bowel disease [26]. Fn may contribute to CRC development by 
invading colonic mucosa and inducing local inflammation and increased expression of cytokines, leading to 
colorectal disease [20,26-29]. More convincing evidence that Fn infection directly contributes to colorectal 
carcinogenesis rather than being a consequence of disease progression derives from two recent reports showing 
that Fn invasion, through its unique FadA adhesion, recruits tumour-infiltrating immune cells and generates an 
oncogenic/pro-inflammatory microenvironment conducive for colorectal neoplasia [30,31].  
 
The aims of our study were to evaluate the presence of Fn in tumour tissue from European CRC patients and to 
further assess bacterial presence in pre-cancerous tissues and stool samples in order to determine whether Fn 
load associates with the adenoma to cancer progression. We also assessed Fn as a prognostic biomarker by 
correlating survival outcomes in CRC patients with bacterial load.  
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Materials and Methods 
Sample Cohorts 
The subjects in this study were derived from three different patient cohorts in Czech Republic (CZ,  #13), 
Germany (DE) and in Ireland (IE). The Czech cohort comprises tumour (n=49) and matched normal tissue 
samples (n=32) from CRC patients diagnosed and treated at the Departments of Surgery and Oncology, at the 
Teaching Hospital and Medical School in Pilsen, and Charles University in Prague, during the period 2008-
2010. In the German CRC cohort (n=45), tumour tissue and matched normal tissue were collected from patients 
undergoing surgery at the University Hospital in Munich. In the Irish cohort, CRC (n=28) and adenoma (n=52) 
patient tissue along with the corresponding matched normal tissue were collected from the Departments of 
Gastroenterology and Surgery, The Adelaide and Meath Hospital in Dublin. Stool samples from CRC (n=7) 
patients, adenoma (n=24; HGD n=10, TVA n=12, TA n=2) patients, and normal controls (n=25) were also 
collected from the Departments of Gastroenterology and Surgery, The Adelaide and Meath Hospital in Dublin. 
The clinical characteristics of our study cohorts are summarised in Table 1.  
 
Fresh tumour samples were obtained from patients during resection of the primary tumour or by biopsy prior to 
any treatment regime (all centres) and adenoma biopsies were obtained at colonoscopy during routine CRC 
screening, without previous CRC diagnosis (Dublin only). The tissue samples were macrodissected and either 
snap frozen in liquid nitrogen (Munich, Prague, Pilsen) or fixed in an RNA stabilization solution (‘RNA later’, 
Ambion, Dublin) for long term storage at –80°C. The control mucosa samples were taken from the 
macroscopically unaffected resection margins of colon tissues or at a distant site in the colorectal tract during 
colonoscopy. The resection margins were microscopically evaluated and only samples free of malignant cells 
were further analysed. Histology was verified by an experienced pathologist at each centre. Clinical follow up 
was obtained for the Czech CRC and Irish CRA cohort, from the hospital clinicians. We excluded patients with 
a history of a bowel disorder such as inflammatory bowel disease, those with polyposis syndromes, and Lynch 
syndrome. 
 
Informed consent was obtained from all participating subjects for these studies in accord with the Helsinki 
declaration. All samples are coded to protect patient anonymity. The study was approved by the Ethical 
Committee of the St. James’s Hospital and Federated Dublin Voluntary Hospitals Joint Research Ethics 
Committee (Ireland), the Human Subjects Committee of the Technische Universität Munich (Germany) and the 
Ethical Commission of the Medical Faculty and Teaching Hospital in Pilsen (Czech Republic). 
 
DNA extraction  
In the Irish cohort, 20-30 mg of tissue were lysed on ice in 400 µL of lysis buffer (50 mmol/L HEPES pH 7.5, 
150 mmol/L NaCl, 5 mmol/L EDTA) and protease inhibitor (Calbiochem, Hampshire, UK) followed by 
sonication on ice for 3x30 seconds. Lysates were centrifuged at 10,000 g for 10 minutes at 4°C. gDNA was then 
extracted using the Norgen All-in-one kit (cat. No. 24200). DNA was quantified using a Nanodrop 2000c 
spectrophotometer (Thermo Scientific, Asheville, NC, USA). 
In the German cohort, 20-30 mg of frozen tissue samples were lysed by digestion with proteinase K and lysis 
buffer and DNA was extracted from the lysate using the QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) 
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following the manufacturer’s instructions. After elution the DNA was quantified using a Nanodrop 1000 
photospectrometer (Peqlab Biotechnologie GmbH, Erlangen, Germany).  
Finally, for the Czech cohort, DNA was similarly extracted using the AllPrep DNA/RNA/Protein Mini Kit and 
by following the manufacturer’s instructions. (Qiagen, Hilden, Germany). The DNA concentration was 
determined using Quant-iTT dsDNA BR Assay Kit (Life Technologies Czech Republic s.r.o., Prague, Czech 
Republic) and Infinite M200 fluorescence reader (Tecan Group Ltd., Mannedorf, Austria). 
 
For stool samples, DNA was extracted from 220 mg sections taken from three different locations per whole 
stool specimen using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) following the 
manufacturer’s instructions. Purified DNA was eluted in 200 mL of the supplied elution buffer and the DNA 
yield was quantified by ultraviolet spectrometry (260/280 nm). Triplicate aliquots of extracted stool DNA per 
patient sample were therefore available for downstream analysis.  
 
Quantitative Real time PCR (qPCR) 
qPCR to quantify levels of Fn in both disease and matched normal tissue from adenoma and CRC patients, as 
well as in stool samples, was performed on the Applied Biosystems (ABI,  #31) 7500 Real Time PCR system. 
Levels of Fn, and that of the internal control prostaglandin transporter (PGT) gene, were measured 
simultaneously from the same gDNA preparation. Each 12 µL reaction consisted of 40 ng template DNA, 400 
nM of each primer set, 400 nM of each probe, and 1 x final concentration of TaqMan
TM
 universal mastermix 
(cat. No. 4304437). Reaction conditions were 2 minutes at 50°C, 10 minutes at 95°C, 60 cycles of 15 seconds at 
95°C and 1 minute at 57°C. Cycle threshold (CT) was calculated using the SDS software on the ABI 7500 
system. A qPCR assay for levels of the common Bacteroides genus was used as an internal control in the stool 
samples [32]. Samples that showed no amplification within 60 cycles were censored and assumed no template 
present or below detection limit. All samples and controls were run in duplicate. 0.01 ng of Fn, strain CC53, 
provided by Dr Robert Holt (Genome Sciences Centre, Vancouver, Canada) was used as a positive control.  
 
Fn levels are given as relative quantification (RQ) and were determined by 2
-ΔCT, where ΔCT is the difference in 
threshold cycle number for the test and reference (PGT for tissue and Bacteroides for stool) gene assay. Fold 
increase of Fn quantification in disease tissue over matched normal colorectal tissue was calculated as 2
-ΔΔCT
. 
Previously published primer and probes were used [20,32] with the following sequences: 
Fusobacteria forward primer, 5’ CAACCATTACTTTAACTCTACCATGTTCA 3’; Fusobacteria reverse 
primer, 5’ GTTGACTTTACAGAAGGAGATTATGTAAAAATC 3’; Fusobacteria FAM probe, 5’ 
TCAGCAACTTGTCCTTCTTGATCTTTAAATGAACC 3’;  
PGT forward primer, 5’ ATCCCCAAAGCACCTGGTTT 3’; PGT reverse primer, 5’ 
AGAGGCCAAGATAGTCCTGGTAA 3’; PGT FAM probe, 5’ CCATCCATGTCCTCATCTC 3’. 
Bacteroides forward primer 5’ TTCAGGCTAGCGCCCATT 3’; Bacteroides reverse primer 5’ 
GGAACTGAGACACGGTCCAAAC 3’; Bacteroides FAM probe 
5’CCAATATTCCTCACTGCTGCCTCCCGTA  3’. 
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Statistical analysis 
Fn levels determined by qPCR are given as 2
-ΔCT
 where ΔCT is median of the difference in CT between test and 
reference gene. This relative quantification (RQ) was log-transformed to be analysed as log2(1/2
-ΔCT
). Wilcoxon 
signed rank test for paired analysis was used to compare levels of Fn in disease versus matched normal tissue. 
Mann-Whitney test was applied to compare two non-paired groups. Kruskal-Wallis test was used to compare 
median levels of Fn between more than two groups such as cohort origin or CRA subgroups. Odds ratios (OR) 
were assessed by binary logistic regression to assess influence of Fn levels on disease group. Further, 
associations between Fn levels and disease progression were analysed by Spearman correlation analysis.  
The ratio of Fn levels between tumour and matched normal colorectal tissue is given as fold increase 2
-ΔΔCT
 
where ΔΔCT is median of the difference of RQDisease and RQNormal. Log-rank test was used to investigate 
differences between survival distributions of subject groups. To stratify subjects by level of fold increase in Fn, 
we first grouped those subjects with undetected Fn in their tumour tissue. The remaining patients with 
detectable Fn in their tumour tissue were separated into tertiles of low, moderate and high fold increase. Cox 
proportional regression was applied to the three subject groups to determine hazard ratio (HR) of Fn on subject 
survival. Investigating if the trichotomised subject groups showed any further differences besides survival 
distributions, chi-square test was used to compare proportions in categorical variable such as chemotherapy or 
TNM staging. 
All statistical analyses were performed in Matlab (MathWorks, Natick, MA, USA) apart from Cox regression 
which was calculated using SPSS (IBM, Armonk, NY, USA) and log-rank test which was assessed using R (R 
project, www.r-project.org). P values ≤ 0.05 were considered statistically significant.  
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Results  
Fusobacterium is more abundant in colorectal cancer tumour versus normal tissue  
We confirmed by qPCR that relative quantification of Fn is significantly raised in the diseased tissue compared 
to the matched normal tissue in all three European cancer cohorts (see Table 1; CZ cohort p=0.0016; DE cohort 
p=0.0001; IE cohort p=0.0063) (Fig. 1). Since levels of Fn are similar in all three cohorts (RQTumour p=0.10; 
RQNormal p=0.35) and there is no significant difference in fold increase (CZ 266-fold, DE 43-fold, IE 9-fold, 
p=0.94), we also pooled the cohorts. Again, we found significantly higher levels in tumour tissue (pooled 
cohorts RQNormal 2
-19
 vs. RQTumour 2
-10
, p<0.0001). Average Fn levels are increased by over 45 fold in the pooled 
cohorts.  
 
The details on cancer stage, location and mutation status are summarized in Table 1. We found no significant 
modification of Fn levels dependent on cancer location (colon vs. rectum), cancer pathology and clinical 
categories, or mutation status (KRAS, BRAF and TP53). 
 
Fusobacterium levels increase with adenoma to cancer progression 
We then investigated Fn infection in an Irish patient cohort with precancerous adenomas. Marginally significant 
Fn over-representation was observed in the adenoma group when diseases tissue was compared to matched 
normal tissue (RQDisease 2
-29
 vs. RQNormal 2
-30
, p=0.06). However, average Fn quantification in disease tissue were 
2
-10
 and 2
-29
 (p=0.0015) in cancer and adenoma respectively, while the matched normal levels were 2
-28
 and 2
-30
 
(p=0.0010) respectively. This increase in Fn load in the disease tissue from CRA to CRC gives a modest but 
significant association with cancer risk compared to adenomas (ORDisease=1.05, p=0.0096). 
This indication that Fn levels may increase during the transition from adenoma to cancer encouraged us to 
investigate levels of Fn within increasingly dysplastic adenoma stages. Adenoma samples were grouped into 
tubular adenoma (TA, n=9), tubulovillous adenoma (TVA, n=26) and high grade dysplasia (HGD, n=17). In 
tubular adenoma and in tubulovillous adenoma, we found levels of Fn to be similar in normal and disease tissue 
(TA RQDisease 2
-29
 vs. RQNormal 2
-30
, p=0.95; TVA RQDisease 2
-30
 vs. RQNormal 2
-29
, p=0.62). However, Fn levels in 
high grade dysplasia are increased in disease tissue (HGD RQDisease 2
-25
 vs. RQNormal 2
-31
, p=0.0148) (Fig. 2).  
 
Fn levels are significantly different between the stages of neoplastic progression (CRC vs. HGD vs. TVA vs. 
TA; RQDisease p=0.0094; RQNormal p=0.0039). Post-hoc tests showed levels are similarly high in cancer and high 
grade dysplasia tissue (RQDisease p=0.12) while they are lower in adenomas when compared to cancers (RQDisease 
TVA vs. CRC, p=0.0013; TA vs. CRC, p=0.0287). Strikingly, levels of Fn increase through adenomatous stage 
progression and from adenoma to cancer in both the disease and normal tissue (RQDisease cor=0.37, p=0.0008; 
RQNormal cor= 0.24, p=0.0328).  
 
Fusobacterium levels associate with patient survival 
As our data indicated that Fn level in disease tissue was associated with disease progression, we next examined 
Fn load in relation to cancer patient outcome. Using 3-5 year patient follow up, which was available for 32 
patients of the Czech cohort, we compared fold increase of Fn of tumour and matched normal colorectal tissue 
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with overall patient survival. We found a significant difference in survival distributions between patients 
without detected Fn in tumour tissue or low fold increase and those with high fold increase (fold increase < 2
5
 
vs. fold increase > 2
16
, p=0.0083) (Fig. 3). Median survival of subjects with high Fn fold increase is 2 years, 
whereas all subjects with low tumour to normal ratio survive more than 3 years. The point estimate of the 
Hazard Ratio for a patient with high Fn fold increase is almost 20 times higher than for a patient with no or low 
fold increase (HR=19.96, 95% CI=1.42-281.42, p=0.0266). Besides difference in survival, there are no further 
significant differences between patients with no/low or high Fn, neither in chemo-/radiotherapy nor in 
TNM/Dukes staging.  
 
Fusobacterium levels in stool samples associate with colorectal disease but do not reflect tissue levels  
To test Fn as a non-invasive biomarker for CRC screening, we measured bacterial levels in DNA extracted from 
56 patient stool samples from the Irish cohort CRC (n = 7), CRA (n = 24), and controls (n = 25). Fn levels in 
CRC patient stool samples were significantly higher than those from subjects with CRA (CRC RQstool 2
-15 
vs. 
CRA RQstool 2
-21
, p=0.0316) and controls (CRC RQstool 2
-15 
vs. RQstool 2
-21 
, p=0.0201) (Fig. 4a). Levels in control 
subjects were equivalent to those from the CRA patients (p=0.94). Bacteroides level was used a reference 
bacterial assay for the stool sample qPCRs. Comparing Fn levels in stool samples with those from the matched 
tissue samples from the same CRC and CRA patients, where available, revealed no correlation between the 
sample types (CRC rho=0.36 p=0.11, CRA rho=0.24 p=0.42) (see Fig. 4b).  
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
Discussion 
The results of this study confirm for the first time in European cohorts previous reports from North America 
[20,21] that Fn is over-represented in tumour tissue compared to normal tissue in colorectal cancers. More 
strikingly this work indicates that Fn load increases with disease progression from adenoma to cancer and may 
also be related to survival from cancer.  
 
The cohorts examined in this study included samples from three distinct European populations; one from 
Ireland, one from Germany, and one from the Czech Republic. In all populations Fn was over-represented in 
disease tissue compared to matched normal tissue.  
 
Fn levels show a distinct increase through the major stages of colorectal neoplasia progression. There was a 
gradual increase in Fn level from TA to TVA through to HGD, which is associated with a high risk, unless 
treated, of progressing to cancer. These data suggest that Fn load is possibly associated with both adenoma 
pathology progression and the transition from adenoma to cancer. While preparing this manuscript, a similar 
pattern of Fn over abundance in adenomas was also reported by two studies from North America [29,30].  
Kostic et al found Fn overabundance in both tissue and stool of CRA patients, when compared to matched 
normal tissue and healthy controls respectively [30]. McCoy and colleagues reported adenoma subjects had a 
significantly higher abundance of Fn compared to controls. However here they examined mucosa biopsies taken 
from the anal verge of the normal rectal mucosa of adenoma patients compared to normal controls rather than 
matched disease and control tissue [29].  
 
Potentially, any impact of Fn infection on adenoma development and progression to more neoplastic lesions will 
be considerable as 95% of all cancers arise from adenomas but only a small number of adenomas become 
cancerous [33,34]. Unfortunately there are no reliable predictive markers of whether an adenoma will advance 
to cancer. Of potential relevance in this context, we also found Fn load in the stool of CRC patients to be 
significantly higher than that of adenoma patients (p=0.0316) and also healthy control patients (p=0.0201), 
although we had a small number of stool samples from CRC patients available for analysis. Interestingly, a 
recent Chinese study examining faecal microbial communities in healthy and CRC groups observed a marked 
increase in the relative abundance of Fn in the CRC cancer cohort compared with the healthy control group [35]. 
Similar trends were reported in a North American study examining Fn abundance in stool samples from healthy 
subjects, CRA subjects, and CRC subjects [30]. However, in our study, Fn levels from stool samples and the 
corresponding disease or matched normal tissue from the same CRC or CRA patient showed no correlation, 
which would limit the value of stool screening for Fn as an individualized CRC screening biomarker. 
Previously, bacterial communities in the colon have also been found to differ significantly to those in the faeces 
[36]. The potential of Fn as a non-invasive CRC screening biomarker needs to be tested in a large study. 
 
The overabundance of Fn in disease vs. normal tissue in both cancers and adenomas prompted us to examine Fn 
levels in relation to patient outcome. We report for the first time a significant association between Fn level and 
patient outcome. Kaplan-Meier analysis indicated that patients with high levels of Fn had a significantly shorter 
survival time, when compared to patients with low levels of Fn. This suggests that Fn may have value as a 
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prognostic indicator and that efforts to eradicate Fn infection could be considered for CRC patients. However, 
our finding is based upon a modest number of patients with an average follow-up time of 3-5 years and thus we 
had limited power to test Fn level as an independent prognostic factor. The use of Fn as an independent 
prognostic biomarker is an intriguing and novel prospect that requires validation in a much larger patient group 
over a longer time-frame. 
 
For those patients with follow-up information available there was no significant association of bacterial levels 
with adenoma recurrence. However, due to the limited follow up time for our adenoma cohort we could not 
more comprehensively access the correlation of Fn levels with either adenoma recurrence or with progression to 
cancer (there were no cancers diagnosed in these patients which was to be expected given the time frame and the 
fact that these adenomas were removed during colonoscopy in the period 2008-2010). A large follow-up study 
examining Fn levels with adenoma recurrence risk would be very desirable, especially for those patients with 
advanced adenomas, as this may provide a screening biomarker for selecting adenomas that are more likely to 
recur, with implications for increasing follow-up stringency and/or anti-microbial treatments for these 
individuals.  
 
Chronic inflammation is an important factor contributing to carcinogenesis, so it is conceivable that the presence 
of Fn may represent an opportunistic passenger infection at an immune-compromised site, and as disease 
progresses more bacteria colonise the site. However, colonic mucosal inflammation linked to Fn invasion and 
increased expression of cytokines has been suggested as a possible mechanism leading to colorectal disease 
[29]. Fn effectively adheres to and invades epithelial cells eliciting an immune response [27,37] and strains 
isolated from inflamed human biopsy material from patients with IBD exhibit a more invasive phenotype [26], 
while a further, recent IBD related study found invasiveness of Fn correlated with increased mRNA expression 
of pro-inflammatory cytokine TNF-α and IL-1β [28]. The same strain of Fn assayed in our study has been 
isolated from CRC tumour tissue and shown to be invasive in a CaCo-2 cell assay [20]. McCoy and colleagues 
[29] showed a significant positive correlation between Fn abundance and TNF-α and IL-10 expression in rectal 
mucosa biopsies from adenoma patients compared to normal controls. During preparation of this manuscript, 
two new studies contributed the most convincing evidence so far that Fn infection directly contributes to 
colorectal carcinogenesis. Employing both in vitro and in vivo methods these studies highlighted Fn 
involvement in promotion of tumorigenesis [30,31]. Using HCT116 Xenograft mice, Rubinstein and colleagues 
demonstrated that Fn  invasion of epithelial cells via FadA binding to E-Cadherin promotes inflammation and 
drives oncogenic signalling [31]. Kostic and co-workers studied Fn infection in the Apc
Min/+ 
mouse model and 
arrived at similar conclusions, implicating Fn in the generation of a proinflammatory microenvironment. Fn 
infection not only increased tumour burden in these mice but also increased infiltrating immune cells in the area 
[30]. Together, these data strongly support a role of Fn-induced mucosal inflammation in colorectal disease. 
 
In summary the findings presented here highlight the emergence of Fn as a risk factor for disease progression 
from adenoma to cancer, and as a possible indicator of survival outcomes in CRC patients.  Further investigation 
is needed to establish whether Fn is actively involved in driving the adenoma to cancer transition in humans or 
is merely an opportunistic passenger, and how Fn infection may affect survival from disease. 
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Table 1: Overview of clinical data of European cohorts (tissue samples). 
NA not applicable or missing; SD standard deviation; CZ Czech; DE Germany; IE Ireland; CRC colorectal 
cancer; CRA colorectal adenoma; RQ relative quantification 
Cohort CZ DE IE IE 
Diagnosis CRC CRC CRC CRA 
Total n of tissue samples 49 45 28 52 
Gender n [male/female] 35/14 24/21 16/12 33/19 
Age mean±SD [years]  70±10 67±11 61±11 63±8 
Location n [colon/rectum] NA 27/18 21/7 30/22 
T staging n [T0/T1/T2/T3/T4] 0/0/1/42/6 1/1/10/26 2/7/2/13/4 NA 
N staging n [Tx/N0/N1/N2/N3] 0/47/2/0/0 1/19/15/10/0 2/19/4/3/0 NA 
M staging n [Mx/M0/M1] 0/49/0 43/0/2 25/0/3 NA 
Dukes staging n [A/B/C/D] 0/47/2/0 NA 9/8/7/4 NA 
Grade n [1/2/3] 6/36/6 1/28/13 NA NA 
KRAS n [wildtype/mutation] 3/2 37/7 15/12 29/22 
BRAF n [wildtype/mutation] 4/0 39/5 24/2 50/1 
TP53 n [wildtype/mutation] NA 27/17 11/2 15/0 
Fusobacterium in disease tissue 
median (inter quartile range) RQ 
2
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 to 2
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Figure legends  
Fig. 1 Fusobacterium in diseased and matched normal colorectal tissue in European CRC cohorts 
Boxplots show median and inter quartile range of relative Fn quantification. Relative quantification is 
significantly higher in colorectal tumour tissue than in matched normal colorectal epithelium tissue, in all CRC 
cohorts (CZ p=0.0016; DE p=0.0001; IE p=0.0063). All cohorts show similar quantification levels, there is 
neither significant difference in tumour tissue (p=0.10) nor in normal tissue (p=0.35). (See supplemental figure 
1 for visualisation of raw data points for each matched tissue sample). 
Fn Fusobacterium nucleatum; CRC colorectal cancer; N normal colorectal epithelium tissue; T colorectal 
tumour tissue; D diseased adenoma tissue; CZ Czech; DE Germany; IE Ireland; n.s. not significant; * significant 
 
Fig. 2 Fusobacterium in diseased and matched normal colorectal tissue of CRC and CRA subjects 
Boxplots show median and inter quartile range of relative Fn quantification. Relative quantification differs 
significantly between diseased tissue of CRC and CRA (p=0.0094). Post-hoc tests show significant difference 
between quantification in tumour tissue and tissue of less advanced forms of adenoma (CRC vs. TA p=0.0287; 
CRC vs. TVA p=0.0013) while more severe adenomas show similar Fn levels as tumour tissue (CRC vs. HGD 
p=0.12). Also, as in CRC, HGD shows elevated Fn quantification in disease tissue compared to matched normal 
colorectal epithelium tissue (p=0.0148), whereas there is no significant difference between tissues in lower 
adenomas (TVA p=0.62; TA p=0.95). (See supplemental figure 2 for visualisation of raw data points for each 
matched tissue sample). 
Fn Fusobacterium nucleatum; CRC colorectal cancer; CRA colorectal adenoma; HGD high grade dysplasia; 
TVA tubulovillous adenoma; TA tubular adenoma; N normal colorectal epithelium tissue; T colorectal tumour 
tissue; D diseased adenoma tissue; IE Ireland; n.s. not significant; * significant 
 
Fig. 3 Overall survival of colorectal cancer subjects associates with increase in Fusobacterium 
quantification  
Kaplan-Meier curves showing overall survival of colorectal cancer (CRC) subjects trichotomised into groups of 
‘no/low’ (blue dotted), ‘moderate’ (black dashed) and ‘high’ (red solid) fold increase of Fn quantification in 
tumour tissue over matched normal epithelial tissue. Subjects with fold increase in Fn > 2
16
 show poor 
prognosis with median survival of 2 years. When no Fn was detected in tumour tissue, or fold increase was < 2
5
, 
then survival at 2 years was still 100%. Survival distributions differ significantly between groups of ‘no/low’ 
and ‘high’ Fn fold increase (p=0.0083). 
 
Fig. 4 Fusobacterium in stool and matched tissue samples of CRC, CRA and healthy subjects 
a) Boxplots show median and inter quartile range of relative Fn quantification in stool samples of CRC, CRA 
and healthy control subjects. Levels are higher in CRC than in CRA (p=0.0316) and controls (p=0.0201), while 
CRA has similar Fn levels as healthy controls (p=0.94). 
b) Relative quantifications of Fn in stool and matched disease tissue samples show no pattern of significant or 
high correlation (CRC rho=0.36 p=0.11, CRA rho=0.24 p=0.42, HGD rho=0.32 p=0.48, TVA rho=0.24 
p=0.70). 
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Fn Fusobacterium nucleatum; CRC colorectal cancer; CRA colorectal adenoma; HGD high grade dysplasia; 
TVA tubulovillous adenoma; TA tubular adenoma; RQ relative quantification; n.s. not significant; * significant  1  2 
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